Cargando…
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data
BACKGROUND: Relapse is common in major depressive disorder (MDD). In this study, we evaluated the incremental health care burden of relapse in patients with MDD. METHODS: This real-world retrospective cohort study used administrative medical and pharmacy claims data to identify commercially insured...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886836/ https://www.ncbi.nlm.nih.gov/pubmed/35232411 http://dx.doi.org/10.1186/s12888-022-03793-7 |
_version_ | 1784660765554245632 |
---|---|
author | Touya, Maëlys Lawrence, Debra F. Kangethe, Anne Chrones, Lambros Evangelatos, Themmi Polson, Michael |
author_facet | Touya, Maëlys Lawrence, Debra F. Kangethe, Anne Chrones, Lambros Evangelatos, Themmi Polson, Michael |
author_sort | Touya, Maëlys |
collection | PubMed |
description | BACKGROUND: Relapse is common in major depressive disorder (MDD). In this study, we evaluated the incremental health care burden of relapse in patients with MDD. METHODS: This real-world retrospective cohort study used administrative medical and pharmacy claims data to identify commercially insured adult patients in the United States diagnosed with MDD who initiated a new antidepressant between January 1, 2012, and September 30, 2017. All-cause health care resource utilization, total costs, and medication adherence were evaluated in two cohorts: patients with and patients without relapse. Relapse was defined as suicide attempts, psychiatric hospitalization, mental health–related emergency department (ED) visit, use of electroconvulsive therapy, or reinitiation of treatment after a gap ≥6 months. RESULTS: The study population included 14,186 patients (7093 baseline-matched patients per cohort). The mean follow-up period was 27.5 and 26.0 months for patients with and patients without relapse, respectively. Patients with relapse had significantly higher rates of hospitalization (16.6% vs 8.5%; p < .0001) and ED visits (54.8% vs 34.7%; p < .0001) than patients without relapse. The total costs for patients with relapse were significantly higher ($12,594 vs $10,445; p < .0001). Patients with relapse were also less adherent to antidepressants (mean proportion of days covered, 0.43 vs 0.49; p < .0001). CONCLUSIONS: Relapse of MDD was associated with increased total costs and health care utilization and lower adherence to antidepressants. Reducing the risk of relapse may result in a reduction of the associated health care burden; however, findings may only be generalizable to patients with commercial insurance. |
format | Online Article Text |
id | pubmed-8886836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88868362022-03-17 Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data Touya, Maëlys Lawrence, Debra F. Kangethe, Anne Chrones, Lambros Evangelatos, Themmi Polson, Michael BMC Psychiatry Research BACKGROUND: Relapse is common in major depressive disorder (MDD). In this study, we evaluated the incremental health care burden of relapse in patients with MDD. METHODS: This real-world retrospective cohort study used administrative medical and pharmacy claims data to identify commercially insured adult patients in the United States diagnosed with MDD who initiated a new antidepressant between January 1, 2012, and September 30, 2017. All-cause health care resource utilization, total costs, and medication adherence were evaluated in two cohorts: patients with and patients without relapse. Relapse was defined as suicide attempts, psychiatric hospitalization, mental health–related emergency department (ED) visit, use of electroconvulsive therapy, or reinitiation of treatment after a gap ≥6 months. RESULTS: The study population included 14,186 patients (7093 baseline-matched patients per cohort). The mean follow-up period was 27.5 and 26.0 months for patients with and patients without relapse, respectively. Patients with relapse had significantly higher rates of hospitalization (16.6% vs 8.5%; p < .0001) and ED visits (54.8% vs 34.7%; p < .0001) than patients without relapse. The total costs for patients with relapse were significantly higher ($12,594 vs $10,445; p < .0001). Patients with relapse were also less adherent to antidepressants (mean proportion of days covered, 0.43 vs 0.49; p < .0001). CONCLUSIONS: Relapse of MDD was associated with increased total costs and health care utilization and lower adherence to antidepressants. Reducing the risk of relapse may result in a reduction of the associated health care burden; however, findings may only be generalizable to patients with commercial insurance. BioMed Central 2022-03-01 /pmc/articles/PMC8886836/ /pubmed/35232411 http://dx.doi.org/10.1186/s12888-022-03793-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Touya, Maëlys Lawrence, Debra F. Kangethe, Anne Chrones, Lambros Evangelatos, Themmi Polson, Michael Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data |
title | Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data |
title_full | Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data |
title_fullStr | Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data |
title_full_unstemmed | Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data |
title_short | Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data |
title_sort | incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886836/ https://www.ncbi.nlm.nih.gov/pubmed/35232411 http://dx.doi.org/10.1186/s12888-022-03793-7 |
work_keys_str_mv | AT touyamaelys incrementalburdenofrelapseinpatientswithmajordepressivedisorderarealworldretrospectivecohortstudyusingclaimsdata AT lawrencedebraf incrementalburdenofrelapseinpatientswithmajordepressivedisorderarealworldretrospectivecohortstudyusingclaimsdata AT kangetheanne incrementalburdenofrelapseinpatientswithmajordepressivedisorderarealworldretrospectivecohortstudyusingclaimsdata AT chroneslambros incrementalburdenofrelapseinpatientswithmajordepressivedisorderarealworldretrospectivecohortstudyusingclaimsdata AT evangelatosthemmi incrementalburdenofrelapseinpatientswithmajordepressivedisorderarealworldretrospectivecohortstudyusingclaimsdata AT polsonmichael incrementalburdenofrelapseinpatientswithmajordepressivedisorderarealworldretrospectivecohortstudyusingclaimsdata |